Raras
Buscar doenças, sintomas, genes...
CLN14 disease
ORPHA:699708CID-10 · E75.4CID-11 · 5C56.1OMIM 611726DOENÇA RARA
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença neurodegenerativa rara associada a mutações no gene KCTD7. Caracteriza-se por epilepsia de início precoce, deficiência intelectual progressiva e distúrbios do movimento.

Pesquisas ativas
1 ensaio
1 total registrados no ClinicalTrials.gov
Publicações científicas
27 artigos
Último publicado: 2026 Feb
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: E75.4
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (6)
0202010279
Dosagem de aminoácidos (erros inatos)metabolic_test
0202010295
Dosagem de ácidos orgânicos na urinagenetic_test
0202010490
Teste de triagem para erros inatos do metabolismonewborn_screening
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202080013
Teste do pezinho (triagem neonatal)
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
20 sintomas
💪
Músculos
3 sintomas
👁️
Olhos
2 sintomas
🦴
Ossos e articulações
1 sintomas

+ 5 sintomas em outras categorias

Características mais comuns

Mioclonia de membro
Acúmulo intracelular em impressão digital de material de armazenamento de lipopigmento autofluorescente
Atrofia cerebral
Crise mioclônica generalizada
Atrofia cerebelar
Deficiência intelectual
31sintomas
Sem dados (31)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 31 características clínicas mais associadas, ordenadas por frequência.

Mioclonia de membroLimb myoclonus
Acúmulo intracelular em impressão digital de material de armazenamento de lipopigmento autofluorescenteFingerprint intracellular accumulation of autofluorescent lipopigment storage material
Atrofia cerebralCerebral atrophy
Crise mioclônica generalizadaGeneralized myoclonic seizure
Atrofia cerebelarCerebellar atrophy

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Total histórico27PubMed
Últimos 10 anos18publicações
Pico20153 papers
Linha do tempo
20202015Hoje · 2026🧪 2020Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição.

KCTD7BTB/POZ domain-containing protein KCTD7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the control of excitability of cortical neurons

LOCALIZAÇÃO

Cell membraneCytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Antigen processing: Ubiquitination & Proteasome degradationNeddylation
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 3, with or without intracellular inclusions

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM3 is an autosomal recessive, severe, form with early onset. Multifocal myoclonic seizures begin between 16 and 24 months of age after normal initial development. Neurodegeneration and regression occur with seizure onset. Other features include intellectual disability, dysarthria, truncal ataxia, and loss of fine finger movements. EEG shows slow dysrhythmia, multifocal and occasionally generalized epileptiform discharges. In some patients, ultrastructural findings on skin biopsies identify intracellular accumulation of autofluorescent lipopigment storage material, consistent with neuronal ceroid lipofuscinosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
27.6 TPM
Útero
24.4 TPM
Cervix Ectocervix
23.9 TPM
Brain Spinal cord cervical c-1
23.6 TPM
Testículo
22.7 TPM
OUTRAS DOENÇAS (1)
progressive myoclonic epilepsy type 3
HGNC:21957UniProt:Q96MP8

Variantes genéticas (ClinVar)

106 variantes patogênicas registradas no ClinVar.

🧬 KCTD7: NM_153033.5(KCTD7):c.338C>G (p.Ser113Ter) ()
🧬 KCTD7: NM_153033.5(KCTD7):c.835C>T (p.Arg279Cys) ()
🧬 KCTD7: GRCh37/hg19 7q11.21-11.23(chr7:65130644-74629034)x4 ()
🧬 KCTD7: NM_153033.5(KCTD7):c.753C>A (p.Asp251Glu) ()
🧬 KCTD7: NM_153033.5(KCTD7):c.514G>T (p.Glu172Ter) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

2 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — CLN14 disease

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Bioenergetic Profiling Applied to a Zebrafish Model of Neuronal Ceroid Lipofuscinosis, a Lysosomal Storage Disorder.

Methods in molecular biology (Clifton, N.J.)2026

Neuronal Ceroid Lipofuscinoses (NCLs) are a group of inherited neurodegenerative disorders characterized by autofluorescent lipopigment accumulation. NCLs consist of various types, spanning from CLN1 to CLN14 (except for "CLN9"), each linked to a particular mutated gene. Although the symptoms exhibit resemblances, the age at which each symptom manifests differs across the distinct types. Mitochondrial impairment has been implicated in the pathogenesis of NCLs, with studies suggesting contributions from dysfunctional oxidative phosphorylation and altered mitochondrial membrane potential to the progressive neurodegeneration observed in affected individuals. Utilizing Seahorse XF Analyzer, this study presents a method for the nuanced exploration of mitochondrial function and cellular metabolism, offering insights into potential therapeutic avenues. Zebrafish models reveal phenotypic similarities to human patients, making them promising for disease studies. Our research optimizes the Seahorse Mito Stress assay at 2 days post-fertilization (dpf) in zebrafish. This emerging approach holds great promise for identifying novel therapies.

#2

Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom.

Orphanet journal of rare diseases2025 May 12

Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, are a group of inherited neurodegenerative disorders that mostly arise in childhood. Each of the NCLs is a genetically distinct disease caused by variants in at least 13 different genes (CLN1-CLN14). NCLs are neurodegenerative, and symptoms can include a combination of childhood dementia, epileptic seizures, motor decline and vision loss, and eventually lead to premature death. There is currently no cure for any subtype of NCL, however, enzyme replacement therapy is available for CLN2 disease, and several treatment strategies are being explored for other NCL subtypes. Early diagnosis and initiation of supportive services (e.g. health, education, social services) are essential to preserve quality of life. Only a few studies have investigated family experiences with NCL, many of which are international in scope. A mixed-method research study was conducted in the UK to understand family experiences in CLN2 and CLN3 disease. It involved an initial literature review, followed by in-depth qualitative interviews. Interview data were analysed using a thematic analysis. Thirteen families (n = 13) participated in the interviews. This represented 16 parents (11 mothers and 5 fathers) of 18 children (10 diagnosed with CLN3 disease and 8 diagnosed with CLN2 disease). Findings were analysed jointly across CLN2 and CLN3 disease. Six overarching themes emerged from the analysis: difficulty in recognising early symptoms; the shock of a diagnosis; the demands of caring for complex and ever-changing needs; a constant battle to access appropriate and timely support services; the extensive impact on the unaffected sibling; and the all-encompassing impact on the family. This study contributes novel UK specific data on family experiences and unmet needs in CLN2 and CLN3 disease. More needs to be done to ensure NCLs are diagnosed early, and timely local support services are made available to protect quality of life for both the affected children and their families.

#3

A novel pathogenic variant in the KCTD7 gene in a patient with neuronal ceroid lipofuscinosis (CLN14): a case report and review of the literature.

BMC neurology2024 Sep 30

Neuronal ceroid lipofuscinosis (NCL) is a heterogeneous group of 13 rare, progressive neurodegenerative diseases of the brain and retina. CLN14 is a very rare subtype of NCL caused by pathogenic variants in the KCTD7 gene. Only four cases of this subtype have been reported in the literature. A nine-month-old, previously healthy male who was firstborn to first-cousin parents presented with progressive psychomotor regression, dysmorphic facial features, myoclonus, and vision loss. Neurological examination showed generalized hypotonia and brisk reflexes. He continued to deteriorate until age 18 months, when he developed his first generalized tonic-clonic seizure. An ophthalmological examination showed a hypopigmented fundus and slight temporal disc pallor. Brain MRI showed mild generalized brain atrophy and white matter disease. EEG revealed a severely abnormal trace marked by generalized, high amplitude, sharply contoured, polymorphic delta slowing intermixed with theta slowing and some alpha activity, with disorganized and scattered spikes and sharp waves. The patient continued to have uncontrolled seizures and further psychomotor regression until he died of status epilepticus and pneumonia at the age of 44 months. WES identified a novel homozygous variant c.413T > C, p.(Leu138Pro) in the KCTD7 gene, causing an amino acid transition from leucine to proline at position 138. Both parents were carriers of the same variant. We present the fifth known case of CLN14 in the literature and report the clinical course and a novel underlying likely causative variant in the KCTD7 gene. The improving accessibility and affordability of genetic testing will likely uncover more NCL cases and further expand the disease's genotypic and phenotypic spectrum.

#4

Clinical and Molecular Characteristics of Neuronal Ceroid Lipofuscinosis in Saudi Arabia.

Pediatric neurology2024 Jun

Neuronal ceroid lipofuscinoses (NCLs) represent a heterogeneous group of inherited metabolic lysosomal disorders characterized by neurodegeneration. This study sought to describe the clinical and molecular characteristics of NCLs in Saudi Arabia and determine the most common types in that population. A retrospective review of electronic medical records was conducted for 63 patients with NCL (55 families) from six tertiary and referral centers in Saudi Arabia between 2008 and 2022. Clinical, radiological, and neurophysiological data as well as genetic diagnoses were reviewed. CLN6 was the predominant type, accounting for 45% of cases in 25 families. The most common initial symptoms were speech delay (53%), cognitive decline (50%) and/or gait abnormalities (48%), and seizure (40%). Behavioral symptomatology was observed in 20%, whereas visual impairment was less frequently (9.3%) encountered. Diffuse cerebral and cerebellar atrophy was the predominant finding on brain magnetic resonance imaging. Electroencephalography generally revealed background slowing in all patients with generalized epileptiform discharges in 60%. The most common genotype detected was the p.Ser265del variant found in 36% (20 of 55 families). The most rapidly progressive subtypes were CLN2 and CLN6. Two patients with each died at age five years. The earliest age at which a patient was nonambulatory was two years in a patient with CLN14. This is the largest molecularly confirmed NCL cohort study from Saudi Arabia. Characterizing the natural history of specific NLC types can increase understanding of the underlying pathophysiology and distinctive genotype-phenotype characteristics, facilitating early diagnosis and treatment initiation as well as genetic counseling for families. The neuronal ceroid lipofuscinoses (NCL), also known as Batten disease, are a group of inherited lysosomal storage disorders that share similar pathological and clinical features. They are characterized by accumulation of autofluorescent storage material within the lysosome and the death of neurons. Clinical presentation includes medically refractory epilepsy, visual failure, and motor and cognitive decline, usually beginning in childhood and ending in premature death. Each NCL is caused by mutations in a single gene and is associated with a typical age of onset and disease progression. However, all NCL also have a broader age of onset and disease course. Considerable expertise has been developed in the care and management of patients. There is one treatment in the clinic and others are in development.

#5

The involvement of Purkinje cells in progressive myoclonic epilepsy: Focus on neuronal ceroid lipofuscinosis.

Neurobiology of disease2023 Sep

The progressive myoclonic epilepsies (PMEs) are a group of rare neurodegenerative diseases characterized by myoclonus, epileptic seizures, and progressive neurological deterioration with cerebellar involvement. They include storage diseases like Gaucher disease, Lafora disease, and forms of neuronal ceroid lipofuscinosis (NCL). To date, 13 NCLs have been reported (CLN1-CLN8, CLN10-CLN14), associated with mutations in different genes. These forms, which affect both children and adults, are characterized by seizures, cognitive and motor impairments, and in most cases visual loss. In NCLs, as in other PMEs, central nervous system (CNS) neurodegeneration is widespread and involves different subpopulations of neurons. One of the most affected regions is the cerebellar cortex, where motor and non-motor information is processed and transmitted to deep cerebellar nuclei through the axons of Purkinje cells (PCs). PCs, being GABAergic, have an inhibitory effect on their target neurons, and provide the only inhibitory output of the cerebellum. Degeneration of PCs has been linked to motor impairments and epileptic seizures. Seizures occur when some insult upsets the normal balance in the CNS between excitatory and inhibitory impulses, causing hyperexcitability. Here we review the role of PCs in epilepsy onset and progression following their PME-related loss. In particular, we focus on the involvement of PCs in seizure phenotype in NCLs, highlighting findings from case reports and studies of animal models in which epilepsy can be linked to PC loss.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 18

2026

Bioenergetic Profiling Applied to a Zebrafish Model of Neuronal Ceroid Lipofuscinosis, a Lysosomal Storage Disorder.

Methods in molecular biology (Clifton, N.J.)
2025

Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom.

Orphanet journal of rare diseases
2024

A novel pathogenic variant in the KCTD7 gene in a patient with neuronal ceroid lipofuscinosis (CLN14): a case report and review of the literature.

BMC neurology
2024

Clinical and Molecular Characteristics of Neuronal Ceroid Lipofuscinosis in Saudi Arabia.

Pediatric neurology
2023

The involvement of Purkinje cells in progressive myoclonic epilepsy: Focus on neuronal ceroid lipofuscinosis.

Neurobiology of disease
2021

Patient-Derived Induced Pluripotent Stem Cell Models for Phenotypic Screening in the Neuronal Ceroid Lipofuscinoses.

Molecules (Basel, Switzerland)
2021

Neuronal Ceroid Lipofuscinoses in Children.

Annals of Indian Academy of Neurology
2021

Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Drugs
2020

Functional Analysis of a Novel CLN5 Mutation Identified in a Patient With Neuronal Ceroid Lipofuscinosis.

Frontiers in genetics
2020

Molecular networking in the neuronal ceroid lipofuscinoses: insights from mammalian models and the social amoeba Dictyostelium discoideum.

Journal of biomedical science
2019

Rapid progression of a walking disability in a 5-year-old boy with a CLN6 mutation.

Brain & development
2018

KCTD7 deficiency defines a distinct neurodegenerative disorder with a conserved autophagy-lysosome defect.

Annals of neurology
2017

CLN5 is cleaved by members of the SPP/SPPL family to produce a mature soluble protein.

Experimental cell research
2016

Using the social amoeba Dictyostelium to study the functions of proteins linked to neuronal ceroid lipofuscinosis.

Journal of biomedical science
2016

Novel missense mutation in CLN8 in late infantile neuronal ceroid lipofuscinosis: The first report of a CLN8 mutation in Japan.

Brain & development
2015

Genetics of the neuronal ceroid lipofuscinoses (Batten disease).

Biochimica et biophysica acta
2015

Human NCL Neuropathology.

Biochimica et biophysica acta
2015

Cell biology of the NCL proteins: What they do and don't do.

Biochimica et biophysica acta

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para CLN14 disease.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para CLN14 disease

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Bioenergetic Profiling Applied to a Zebrafish Model of Neuronal Ceroid Lipofuscinosis, a Lysosomal Storage Disorder.
    Methods in molecular biology (Clifton, N.J.)· 2026· PMID 41082122mais citado
  2. Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom.
    Orphanet journal of rare diseases· 2025· PMID 40355884mais citado
  3. A novel pathogenic variant in the KCTD7 gene in a patient with neuronal ceroid lipofuscinosis (CLN14): a case report and review of the literature.
    BMC neurology· 2024· PMID 39350080mais citado
  4. Clinical and Molecular Characteristics of Neuronal Ceroid Lipofuscinosis in Saudi Arabia.
    Pediatric neurology· 2024· PMID 38653183mais citado
  5. The involvement of Purkinje cells in progressive myoclonic epilepsy: Focus on neuronal ceroid lipofuscinosis.
    Neurobiology of disease· 2023· PMID 37573956mais citado
  6. KCTD7-related progressive myoclonic epilepsy: Clinical and genetic characterization of six Indian patients and review of literature.
    Seizure· 2026· PMID 41564653recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:699708(Orphanet)
  2. MONDO:0012721(MONDO)
  3. GARD:2167(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

CLN14 disease

ORPHA:699708 · MONDO:0012721
CID-10
E75.4 · Lipofuscinose neuronal ceróide
CID-11
OMIM
611726
Ensaios
1 ativos
MedGen
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades